Fundamentals of FGF19 & FGF21 Action In Vitro and In Vivo

被引:98
作者
Adams, Andrew C. [1 ]
Coskun, Tamer [1 ]
Rovira, Armando R. Irizarry [1 ]
Schneider, Michael A. [1 ]
Raches, David W. [1 ]
Micanovic, Radmila [1 ]
Bina, Holly A. [1 ]
Dunbar, James D. [1 ]
Kharitonenkov, Alexei [1 ]
机构
[1] Lilly Corp Ctr, Lilly Res Labs, Indianapolis, IN 46285 USA
来源
PLOS ONE | 2012年 / 7卷 / 05期
关键词
FIBROBLAST GROWTH-FACTORS; KLOTHO GENE FAMILY; FACTOR RECEPTOR 4; BETA-KLOTHO; INSULIN-RESISTANCE; METABOLIC-ACTIVITY; PPAR-ALPHA; FIBROBLAST-GROWTH-FACTOR-21; OBESITY; MICE;
D O I
10.1371/journal.pone.0038438
中图分类号
O [数理科学和化学]; P [天文学、地球科学]; Q [生物科学]; N [自然科学总论];
学科分类号
07 ; 0710 ; 09 ;
摘要
Fibroblast growth factors 19 (FGF19) and 21 (FGF21) have emerged as key regulators of energy metabolism. Several studies have been conducted to understand the mechanism of FGF19 and FGF21 action, however, the data presented has often been inconsistent and at times contradictory. Here in a single study we compare the mechanisms mediating FGF19/FGF21 actions, and how similarities/differences in actions at the cellular level between these two factors translate to common/divergent physiological outputs. Firstly, we show that in cell culture FGF19/FGF21 are very similar, however, key differences are still observed differentiating the two. In vitro we found that both FGF's activate FGFRs in the context of beta Klotho (KLB) expression. Furthermore, both factors alter ERK phosphorylation and glucose uptake with comparable potency. Combination treatment of cells with both factors did not have additive effects and treatment with a competitive inhibitor, the FGF21 delta N17 mutant, also blocked FGF19' s effects, suggestive of a shared receptor activation mechanism. The key differences between FGF21/FGF19 were noted at the receptor interaction level, specifically the unique ability of FGF19 to bind/signal directly via FGFR4. To determine if differential effects on energy homeostasis and hepatic mitogenicity exist we treated DIO and ob/ob mice with FGF19/FGF21. We find comparable efficacy of the two proteins to correct body weight and serum glucose in both DIO and ob/ob mice. Nevertheless, FGF21 and FGF19 had distinctly different effects on proliferation in the liver. Interestingly, in vivo blockade of FGF21 signaling in mice using Delta N17 caused profound changes in glycemia indicative of the critical role KLB and FGF21 play in the regulation of glucose homeostasis. Overall, our data demonstrate that while subtle differences exist in vitro the metabolic effects in vivo of FGF19/FGF21 are indistinguishable, supporting a shared mechanism of action for these two hormones in the regulation of energy balance.
引用
收藏
页数:11
相关论文
共 42 条
  • [1] Badman MK, 2007, CELL METAB, V5, P426, DOI 10.1016/j.cmet.2007.05.002
  • [2] Badman MK, 2009, AM J PHYSL ENDOCRINO
  • [3] Chen Gregory J, 2006, Recent Pat Cardiovasc Drug Discov, V1, P211, DOI 10.2174/157489006777442478
  • [4] Fibroblast Growth Factor 21 Corrects Obesity in Mice
    Coskun, Tamer
    Bina, Holly A.
    Schneider, Michael A.
    Dunbar, James D.
    Hu, Charlie C.
    Chen, Yanyun
    Moller, David E.
    Kharitonenkov, Alexei
    [J]. ENDOCRINOLOGY, 2008, 149 (12) : 6018 - 6027
  • [5] Best practices guideline: T6oxicologic histopathology
    Crissman, JW
    Goodman, DG
    Hildebrandt, PK
    Maronpot, RR
    Prater, DA
    Riley, JH
    Seaman, WJ
    Thake, DC
    [J]. TOXICOLOGIC PATHOLOGY, 2004, 32 (01) : 126 - 131
  • [6] Integrated Regulation of Hepatic Metabolism by Fibroblast Growth Factor 21 (FGF21) in Vivo
    Fisher, Ffolliott M.
    Estall, Jennifer L.
    Adams, Andrew C.
    Antonellis, Patrick J.
    Bina, Holly A.
    Flier, Jeffrey S.
    Kharitonenkov, Alexei
    Spiegelman, Bruce M.
    Maratos-Flier, Eleftheria
    [J]. ENDOCRINOLOGY, 2011, 152 (08) : 2996 - 3004
  • [7] Obesity Is a Fibroblast Growth Factor 21 (FGF21)-Resistant State
    Fisher, Ffolliott M.
    Chui, Patricia C.
    Antonellis, Patrick J.
    Bina, Holly A.
    Kharitonenkov, Alexei
    Flier, Jeffrey S.
    Maratos-Flier, Eleftheria
    [J]. DIABETES, 2010, 59 (11) : 2781 - 2789
  • [8] Fibroblast growth factor 19 increases metabolic rate I and reverses dietary and leptlin-deficient diabetes
    Fu, L
    John, LM
    Adams, SH
    Yu, XX
    Tomlinson, E
    Renz, M
    Williams, PM
    Soriano, R
    Corpuz, R
    Moffat, B
    Vandlen, R
    Simmons, L
    Foster, J
    Stephan, JP
    Tsai, SP
    Stewart, TA
    [J]. ENDOCRINOLOGY, 2004, 145 (06) : 2594 - 2603
  • [9] Goetz R, 2012, MOL CELL BIOL
  • [10] Lack of Overt FGF21 Resistance in Two Mouse Models of Obesity and Insulin Resistance
    Hale, Clarence
    Chen, Michelle M.
    Stanislaus, Shanaka
    Chinookoswong, Narumol
    Hager, Todd
    Wang, Minghan
    Veniant, Murielle M.
    Xu, Jing
    [J]. ENDOCRINOLOGY, 2012, 153 (01) : 69 - 80